Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ricardo Rao

Vascular Surgery Saint Louis, MO Medical Doctor

NPI 1427029362 CMS profile 337394

3023 N Ballas Rd, Suite 210D, Saint Louis, MO 63131

Open in the dashboard

General payments

$7,640

128 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ricardo Rao of Saint Louis, MO is reported in the CMS Open Payments database as having received $7,640 across 128 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $441 15
2024 General $390 8
2023 General $597 16
2022 General $527 20
2021 General $734 21
2020 General $3,165 10
2019 General $1,787 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ricardo Rao
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Ricardo Rao were reported at $441. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Ricardo Rao Vascular Surgery median Middle half National median
2019 $1,787 $796 $226–$2,363 $163
2020 $3,165 $348 $118–$1,110 $114
2021 $734 $471 $158–$1,421 $132
2022 $527 $725 $222–$2,183 $149
2023 $597 $836 $257–$2,440 $160
2024 $390 $909 $252–$2,619 $164
2025 $441 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. IDev Technologies, Inc. $2,896 1 payment
  2. Philips Electronics North America Corporation $1,855 31 payments
  3. Smith+Nephew, Inc. $300 12 payments
  4. Silk Road Medical, Inc. $218 1 payment
  5. Janssen Pharmaceuticals, Inc $184 10 payments
  6. Bard Peripheral Vascular, Inc. $171 2 payments
  7. Organogenesis Inc. $155 8 payments
  8. Biotronik Inc. $143 1 payment
  9. Boston Scientific Corporation $136 2 payments
  10. E.R. Squibb & Sons, L.L.C. $123 8 payments
  11. Other $1,461 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,745 127 payments
  2. Current or prospective ownership or investment interest $2,896 1 payment
Products named General payments · program years 2019–2025
  1. Lasers $802 12 payments
  2. Stellarex Long $412 7 payments
  3. COLLAGENASE SANTYL $224 8 payments
  4. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $218 1 payment
  5. ENROUTE Transcarotid Stent $218 1 payment
  6. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $218 1 payment
  7. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $218 1 payment
  8. XARELTO $184 10 payments
  9. (6342) Intrasight Integrated $135 2 payments
  10. (6554) Periph Vasc Undiv $125 1 payment
  11. Other $2,721 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

384

Median for Vascular Surgery: 122

Drug cost

$8,282

Median for Vascular Surgery: $14,135

Branded share of claims

10.2%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pentoxifylline Generic 74 $3,001
Gentamicin Sulfate Generic 23 $1,410
Doxycycline Hyclate Generic 83 $1,048
Clobetasol Propionate Generic 13 $950
Cefadroxil Generic 42 $556
Cilostazol Generic 16 $233
Gabapentin Generic 17 $217
Clopidogrel Clopidogrel Bisulfate Brand 22 $197
Clindamycin Hcl Generic 12 $136
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 17 $132

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$73,072

Medicare's payments for the services billed

Medicare patients

300

Average age 78

Services billed

1,506

159 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Ischemic heart disease 45%
Chronic kidney disease 43%
Atrial fibrillation 41%
Heart failure 40%
Depression 39%
Diabetes 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

128 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record